Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lebrikizumab

lebrikizumab

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of lebrikizumab

14 trials tracked of lebrikizumab: 10 in phase 3 or 4 and 9 with published results. The most-cited published study has 139 citations.

14Trials tracked
10Phase 3 & 4
0Recruiting
9With published results
Phase distribution
Phase 3 10 Phase 2 2 Phase 1 2
  1. Phase 3 Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. Completed · 139 cited
  2. Phase 3 Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Completed · 42 cited
  3. Phase 3 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate1) Completed · 12 cited
  4. Phase 3 Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis Completed · 11 cited
  5. Phase 3 Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) Completed · 7 cited
  6. Phase 3 A Study of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroids in Japanese Participants With Moderate-to-Severe Atopic Dermatitis Completed · 7 cited
Show 8 more trials
  1. Phase 3 A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color Completed · 6 cited
  2. Phase 3 A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA) Completed · 3 cited
  3. Phase 3 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab Completed · 2 cited
  4. Phase 3 A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine Completed
  5. Phase 2 A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis Completed
  6. Phase 2 A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Completed
  7. Phase 1 A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants Completed
  8. Phase 1 A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants Completed

Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis
Dermatology RCT
Secondary analysis of Phase 3 trials shows lebrikizumab improves absolute EASI response in moderate-to-severe atopic dermatitis New analysis shows lebrikizumab helps clear skin faster than placebo for atopic dermatitis
This secondary analysis of two Phase 3 trials evaluated lebrikizumab 250 mg Q2W versus placebo in adults and adolescents with moderate-to-se…
A look at two major trials found lebrikizumab led to significantly better skin clearing than placebo in adults and adolescents with moderate…
May 21, 2026